M J Morris1, M A Eisenberger2, R Pili2, S R Denmeade2, D Rathkopf3, S F Slovin3, J Farrelly4, J J Chudow4, M Vincent5, H I Scher3, M A Carducci2. 1. Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York; Department of Medicine, Weill Cornell Medical College, New York. Electronic address: morrism@mskcc.org. 2. Department of Oncology, Prostate Cancer and Chemical Therapeutics Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore. 3. Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York; Department of Medicine, Weill Cornell Medical College, New York. 4. Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York. 5. Agensys Inc., An Affiliate of Astellas Pharma Inc., Santa Monica, USA.
Abstract
BACKGROUND: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in progressive castration-resistant prostate cancer. PATIENTS AND METHODS: Twenty-nine patients were administered infusions of AGS-PSCA (1-40 mg/kg) every 3 weeks for 12 weeks; 18 final patients received a 40-mg/kg loading dose followed by 20-mg/kg repeat doses. Primary end points were safety and PK. Immunogenicity, antitumor activity and circulating tumor cells were also evaluated. RESULTS: No drug-related serious adverse events were noted. Dose escalation stopped before reaching the maximum tolerated dose as target concentrations were achieved. Drug levels accumulated linearly with dose and the mean terminal half-life was 2-3 weeks across dose levels. The 40-mg/kg loading dose followed by repeated 20-mg/kg doses yielded serum drug concentrations above the projected minimum therapeutic threshold after two to three doses without excessive drug accumulation or toxicity. Significant antitumor effects were not seen. CONCLUSIONS: A 40-mg/kg loading dose followed by 20-mg/kg infusions every 3 weeks is the recommended phase II dose of AGS-PSCA. PSCA is a promising drug target and studies in prostate and other relevant solid tumors are planned.
BACKGROUND: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in progressive castration-resistant prostate cancer. PATIENTS AND METHODS: Twenty-nine patients were administered infusions of AGS-PSCA (1-40 mg/kg) every 3 weeks for 12 weeks; 18 final patients received a 40-mg/kg loading dose followed by 20-mg/kg repeat doses. Primary end points were safety and PK. Immunogenicity, antitumor activity and circulating tumor cells were also evaluated. RESULTS: No drug-related serious adverse events were noted. Dose escalation stopped before reaching the maximum tolerated dose as target concentrations were achieved. Drug levels accumulated linearly with dose and the mean terminal half-life was 2-3 weeks across dose levels. The 40-mg/kg loading dose followed by repeated 20-mg/kg doses yielded serum drug concentrations above the projected minimum therapeutic threshold after two to three doses without excessive drug accumulation or toxicity. Significant antitumor effects were not seen. CONCLUSIONS: A 40-mg/kg loading dose followed by 20-mg/kg infusions every 3 weeks is the recommended phase II dose of AGS-PSCA. PSCA is a promising drug target and studies in prostate and other relevant solid tumors are planned.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: John S Lam; Joyce Yamashiro; I Peter Shintaku; Robert L Vessella; Robert B Jenkins; Steve Horvath; Jonathan W Said; Robert E Reiter Journal: Clin Cancer Res Date: 2005-04-01 Impact factor: 12.531
Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245
Authors: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer Journal: N Engl J Med Date: 2010-07-29 Impact factor: 91.245
Authors: D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits Journal: Proc Natl Acad Sci U S A Date: 2001-02-13 Impact factor: 11.205
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: P Argani; C Rosty; R E Reiter; R E Wilentz; S R Murugesan; S D Leach; B Ryu; H G Skinner; M Goggins; E M Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Cancer Res Date: 2001-06-01 Impact factor: 12.701
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ken-Ryu Han; David B Seligson; Xueli Liu; Steve Horvath; Peter I Shintaku; George V Thomas; Jonathan W Said; Robert E Reiter Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Elham Pishali Bejestani; Marc Cartellieri; Ralf Bergmann; Armin Ehninger; Simon Loff; Michael Kramer; Johannes Spehr; Antje Dietrich; Anja Feldmann; Susann Albert; Martin Wermke; Michael Baumann; Mechthild Krause; Martin Bornhäuser; Gerhard Ehninger; Michael Bachmann; Malte von Bonin Journal: Oncoimmunology Date: 2017-06-20 Impact factor: 8.110
Authors: Jorge A Carrasquillo; Bernard M Fine; Neeta Pandit-Taskar; Steven M Larson; Stephen E Fleming; Josef J Fox; Sarah M Cheal; Joseph A O'Donoghue; Shutian Ruan; Govind Ragupathi; Serge K Lyashchenko; John L Humm; Howard I Scher; Mithat Gönen; Simon P Williams; Daniel C Danila; Michael J Morris Journal: J Nucl Med Date: 2019-05-03 Impact factor: 10.057
Authors: B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo Journal: Ann Oncol Date: 2013-02-28 Impact factor: 32.976
Authors: Hyuna Sung; Nan Hu; Howard H Yang; Carol A Giffen; Bin Zhu; Lei Song; Hua Su; Chaoyu Wang; Dominick M Parisi; Alisa M Goldstein; Philip R Taylor; Paula L Hyland Journal: Carcinogenesis Date: 2017-10-26 Impact factor: 4.944
Authors: Indu Kohaar; Patricia Porter-Gill; Petra Lenz; Yi-Ping Fu; Adam Mumy; Wei Tang; Andrea B Apolo; Nathaniel Rothman; Dalsu Baris; Alan R Schned; Kris Ylaya; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Stephen M Hewitt; Lee E Moore; Ludmila Prokunina-Olsson Journal: J Natl Cancer Inst Date: 2012-12-23 Impact factor: 13.506